Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.


Friday’s trading has closed, but CPHD is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 3:59pm ET
 -0.33 / -0.75%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Cepheid operates as a molecular diagnostics company, which develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the company's legacy industrial, biothreat and partner markets. The company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. It operates through two principal systems: GeneXpert and SmartCycler. The GeneXpert system, the company's primary offering in the clinical market, integrates sample preparation in addition to DNA amplification and detection. It is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Cepheid was founded by Thomas L. Gutshall, William McMillan, Kurt Petersen, Greg Kovacs, and Allen M. Northrup on March 4, 1996 and is headquartered in Sunnyvale, CA.

Contact Information

904 Caribbean Drive
Sunnyvale California 94089-1189
P:(408) 541-4191
Investor Relations:
(408) 400-8329



Mutual fund holders63.14%
Other institutional38.49%
Individual stakeholders3.73%

Top Executives

John L. BishopChairman & Chief Executive Officer
Warren C. KocmondChief Operating Officer & Executive Vice President
Daniel MaddenChief Financial Officer & Executive Vice President
David H. PersingDirector, EVP, Chief Medical & Technical Officer
Kerry FlomChief Regulatory Officer & Executive VP